Biotech: “we are pleased to announce an oversubscribed Series A financing for our 🇨🇳 licensed preclinical TCE” Tech:

In partnership with Vinod Khosla (@vkhosla), I’m proud to introduce Reservoir. Billionaires have owned their cells for years. Starting today, you can too. Sign up today: withreservoir.com

Recursion Announces New Clinical Data Across Two Potential First-in-Class Programs, Sanofi Partnership Milestone, and Oversubscribed $200M Offering Today, we announced important progress across our clinical pipeline, partnerships, and capital position—reflecting growing evidence of what our integrated AI-enabled drug discovery platform can deliver. 🚀 REC-4881 | Deep, durable polyp reductions in FAP In an expanded adult population (18+), 87% of patients achieved polyp burden reductions after 12 weeks (47% median), with 85% remaining below baseline after 12 weeks off treatment. In the upper GI—the area of greatest unmet need—92% achieved reductions (55% median), including two patients with near-complete reductions (≥98%). Of those with reductions, 92% remained below baseline after 12 weeks off treatment. With no approved pharmacologic therapies for FAP, we are targeting registrational trial initiation in 2H 2027, pending FDA discussions. Full data will be presented November 2 at CGA-IGC. 🚀 REC-1245 | Encouraging early activity in heavily pretreated cancer patients Our potential first-in-class oral RBM39 degrader demonstrated three partial responses (two confirmed in endometrial cancer; one unconfirmed in liver cancer) and 91.7% disease control (11/12) at doses ≥45 mg. No dose-limiting toxicities or treatment-related serious adverse events were observed at the selected 45 mg expansion dose. 🚀 Sanofi | First development candidate optioned Two challenging targets, one oral molecule. A potential first-in-class candidate for inflammatory disease, enabled by Recursion’s AI platform and small-molecule chemistry capabilities alongside Sanofi’s expertise. Phase 1 expected in 2027, marking the sixth progress-based milestone across our collaboration. 🚀 $200M Oversubscribed Follow-On Offering | Extending Runway Into 2029 Broad demand from leading healthcare specialists, long-only institutions, and growth investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, and Driehaus Capital Management. The financing supports advancement of our clinical pipeline, continued AI engine innovation, and strategic partnerships. Multiple independent proof points. Across diseases, programs, and partnerships. Powered by one integrated AI-enabled engine. Thank you to our employees, collaborators, clinical investigators, patients, and investors who make this progress possible. Links below 👇 Business Update: ir.recursion.com/news-releas… Sanofi announcement: ir.recursion.com/news-releas… Public offering: ir.recursion.com/news-releas…

Enveda has collected a $311M Series E, at ~$2B post-money valuation, to fuel its pipeline into 2029 the CO and India biotech is in clinical testing w/experimental medicines for eczema, asthma & weight-loss maintenance spoke w/@enveda CEO @viswacolluru: endpoints.news/enveda-raises…

I'm really grateful that @RecursionChris has chosen to join @_DimensionCap. I'm fortunate to be able to speak and learn from him so regularly. When I was getting started on the buy-side, I initially focused entirely on public companies. I was lucky enough to meet Chris and his team at Recursion during their IPO process. As a young and naive person, it was career-altering for me to get the chance to absorb what the company was doing. Chris was, by far, one of the most willing and open individuals I'd met on a public c-suite. Now that I'm older and wiser, I can appreciate even more that he didn't have to do that. He didn't have to speak to an early 20-something. But he did anyway, and it speaks to the type of person Chris is. He's selfless and incredibly driven. Moreover, that relationship also helped me get closer with @nanli, @zavaindar, and @AGoulburn, whom I owe just as much! So now I'm here and so grateful to all be pushing in the same direction.

I heard @endpts is saving that for a collab with the @WWE for season 35 of Raw.

People are still generating “ML datasets” with all kinds of confounds. If the controls are all next to each other on the edge of the plate, no randomization, ngmi.

loyal on 60 minutes this weekend!